• N Strand, C Wie, J Peck, M Maita, N Singh, J Dumbroff, V Tieppo Francio, M Murphy, K Chang, D M Dickerson, and J Maloney.
• Division of Pain Medicine, Mayo Clinic Hospital, Phoenix, AZ, USA. strand.natalie@mayo.edu.
• Curr Pain Headache Rep. 2022 Jun 1; 26 (6): 429-438.

Purpose Of ReviewThis narrative review aims to summarize advances in the field of small fiber neuropathy made over the last decade, with emphasis on novel research highlighting the distinctive features of SFN.Recent FindingsWhile the management of SFNs is ideally aimed at treating the underlying cause, most patients will require pain control via multiple, concurrent therapies. Herein, we highlight the most up-to-date information for diagnosis, medication management, interventional management, and novel therapies on the horizon. Despite the prevalence of small fiber neuropathies, there is no clear consensus on guidelines specific for the treatment of SFN. Despite the lack of specific guidelines for SFN treatment, the most recent general neuropathic pain guidelines are based on Cochrane studies and randomized controlled trials (RCTs) which have individually examined therapies used for the more commonly studied SFNs, such as painful diabetic neuropathy and HIV neuropathy. The recommendations from current guidelines are based on variables such as number needed to treat (NNT), safety, ease of use, and effect on quality of life.© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

18 keywords...

hide…